These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 10472556)

  • 21. Long-term results of the AIEOP-ALL-95 Trial for Childhood Acute Lymphoblastic Leukemia: insight on the prognostic value of DNA index in the framework of Berlin-Frankfurt-Muenster based chemotherapy.
    Aricò M; Valsecchi MG; Rizzari C; Barisone E; Biondi A; Casale F; Locatelli F; Lo Nigro L; Luciani M; Messina C; Micalizzi C; Parasole R; Pession A; Santoro N; Testi AM; Silvestri D; Basso G; Masera G; Conter V
    J Clin Oncol; 2008 Jan; 26(2):283-9. PubMed ID: 18182669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: the Tokyo Children's Cancer Study Group Study L99-15.
    Manabe A; Ohara A; Hasegawa D; Koh K; Saito T; Kiyokawa N; Kikuchi A; Takahashi H; Ikuta K; Hayashi Y; Hanada R; Tsuchida M;
    Haematologica; 2008 Aug; 93(8):1155-60. PubMed ID: 18519521
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The influence of maximum supportive care on dose compliance and survival. Single-center analysis of childhood acute lymphoblastic leukemia and non-Hodgkin's-lymphoma treated within 1984-1993.
    Urban C; Benesch M; Lackner H; Schwinger W; Kerbl R; Gadner H
    Klin Padiatr; 1997; 209(4):235-42. PubMed ID: 9293456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
    Veerman AJ; Kamps WA; van den Berg H; van den Berg E; Bökkerink JP; Bruin MC; van den Heuvel-Eibrink MM; Korbijn CM; Korthof ET; van der Pal K; Stijnen T; van Weel Sipman MH; van Weerden JF; van Wering ER; van der Does-van den Berg A;
    Lancet Oncol; 2009 Oct; 10(10):957-66. PubMed ID: 19747876
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Results of the CCLSG high risk ALL 874 protocol in childhood acute lymphoblastic leukemia. Children's Cancer and Leukemia Study Group].
    Kawai S; Fujimoto T; Zha Z; Asami K; Oka T; Kaneko Y; Takaue Y; Ninomiya T; Nishikawa K; Tsuchiya T
    Rinsho Ketsueki; 1993 Feb; 34(2):128-36. PubMed ID: 8492409
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of acute lymphoblastic leukaemia in countries with limited resources; lessons from use of a single protocol in India over a twenty year period [corrected].
    Magrath I; Shanta V; Advani S; Adde M; Arya LS; Banavali S; Bhargava M; Bhatia K; Gutiérrez M; Liewehr D; Pai S; Sagar TG; Venzon D; Raina V
    Eur J Cancer; 2005 Jul; 41(11):1570-83. PubMed ID: 16026693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic factors for relapsed childhood acute lymphoblastic leukemia: impact of allogeneic stem cell transplantation--a report from the Kyushu-Yamaguchi Children's Cancer Study Group.
    Matsuzaki A; Nagatoshi Y; Inada H; Nakayama H; Yanai F; Ayukawa H; Kawakami K; Moritake H; Suminoe A; Okamura J
    Pediatr Blood Cancer; 2005 Aug; 45(2):111-20. PubMed ID: 15782402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Israel national childhood acute lymphoblastic leukemia study].
    Stark B; Abramov A; Attias D; Balin A; Burstein Y; Barak Y; Jaber L; Goshen Y; Dvir A; Hagai E
    Harefuah; 1990 Apr; 118(7):373-82. PubMed ID: 2351344
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Prognostic value of both detection of lymphoblasts in the period of early treatment and minimal residual disease in childhood acute lymphoblastic leukemia].
    Tie LJ; Gu LJ; Song DL; Jiang LM; Xue HL; Tang JY; Dong L; Pan C; Chen J; Ye H; Wang YP; Chen J
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):6-9. PubMed ID: 15946500
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of acute lymphoblastic leukemia in childhood and adolescence: results of the multicenter therapy study ALL-BFM 81].
    Schrappe M; Beck J; Brandeis WE; Feickert HJ; Gadner H; Graf N; Havers W; Henze G; Jobke A; Kornhuber B
    Klin Padiatr; 1987; 199(3):133-50. PubMed ID: 3306128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Initial response to therapy as an important prognostic factor in acute lymphoblastic leukemia in childhood. COALL study group].
    Janka-Schaub GE; Stührk H; Kortüm B; Graubner U; Jürgens H; Spaar HJ; Schöck V; Dohrn B; Bahr R; Winkler K
    Klin Padiatr; 1991; 203(4):231-5. PubMed ID: 1942930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
    Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
    Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term outcome in children with relapsed ALL by risk-stratified salvage therapy: results of trial acute lymphoblastic leukemia-relapse study of the Berlin-Frankfurt-Münster Group 87.
    Einsiedel HG; von Stackelberg A; Hartmann R; Fengler R; Schrappe M; Janka-Schaub G; Mann G; Hählen K; Göbel U; Klingebiel T; Ludwig WD; Henze G
    J Clin Oncol; 2005 Nov; 23(31):7942-50. PubMed ID: 16258094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Corticosteroid-dependent reduction of leukocyte count in blood as a prognostic factor in acute lymphoblastic leukemia in childhood (therapy study ALL-BFM 83)].
    Riehm H; Reiter A; Schrappe M; Berthold F; Dopfer R; Gerein V; Ludwig R; Ritter J; Stollmann B; Henze G
    Klin Padiatr; 1987; 199(3):151-60. PubMed ID: 3306129
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Acute lymphoblastic leukemia in childhood: the COALL studies].
    Janka GE; Winkler K; Jürgens H; Göbel U; Gutjahr P; Spaar HJ
    Klin Padiatr; 1986; 198(3):171-7. PubMed ID: 3523023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
    Lönnerholm G; Thörn I; Sundström C; Frost BM; Flaegstad T; Heyman M; Jonsson OG; Harila-Saari A; Madsen HO; Porwit A; Schmiegelow K; Söderhäll S; Wesenberg F; Vettenranta K; Larsson R; Forestier E
    Leuk Res; 2011 Apr; 35(4):472-8. PubMed ID: 20961616
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Which steroids should we choose for the treatment of adult acute lymphoblastic leukemia?
    Zheng C; Liu X; Wu J; Cai X; Zhu W; Sun Z
    Am J Hematol; 2010 Oct; 85(10):817-8. PubMed ID: 20815080
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro drug sensitivity testing can predict induction failure and early relapse of childhood acute lymphoblastic leukemia.
    Hongo T; Yajima S; Sakurai M; Horikoshi Y; Hanada R
    Blood; 1997 Apr; 89(8):2959-65. PubMed ID: 9108416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The COALL-85 cooperative study for risk patients with acute lymphatic leukemia: initial results].
    Janka-Schaub GE; Winkler K; Göbel U; Graubner U; Schwenger M; Haas RJ; Jürgens H; Spaar J
    Klin Padiatr; 1988; 200(3):171-6. PubMed ID: 3062253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The long-term impact of in vitro drug sensitivity on risk stratification and treatment outcome in acute lymphoblastic leukemia of childhood (CoALL 06-97).
    Escherich G; Tröger A; Göbel U; Graubner U; Pekrun A; Jorch N; Kaspers G; Zimmermann M; zur Stadt U; Kazemier K; Pieters R; Den Boer ML; Horstmann M; Janka GE;
    Haematologica; 2011 Jun; 96(6):854-62. PubMed ID: 21330320
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.